Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
559
-
Total 13F shares, excl. options
-
121M
-
Shares change
-
+1.27M
-
Total reported value, excl. options
-
$33.4B
-
Value change
-
+$488M
-
Put/Call ratio
-
0.92
-
Number of buys
-
305
-
Number of sells
-
-227
-
Price
-
$275.03
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q3 2024
682 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2024.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 559 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 121M shares
of 132M outstanding shares and own 92.28% of the company stock.
Largest 10 shareholders include Capital World Investors (16.5M shares), FMR LLC (14.7M shares), VANGUARD GROUP INC (12.6M shares), BlackRock, Inc. (9.71M shares), Capital Research Global Investors (5.24M shares), WELLINGTON MANAGEMENT GROUP LLP (4.95M shares), BAILLIE GIFFORD & CO (4.89M shares), Capital International Investors (3.97M shares), Dodge & Cox (3.62M shares), and STATE STREET CORP (3.47M shares).
This table shows the top 559 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.